Financing channel feed – Endpoints News

Financing channel feed

Japan's SoftBank plots billions in biotech investments in move that could keep the valuation flood rising — report

5 years ago

Six years separated from a rabies vaccine scandal, China’s YishengBio grabs $130M to go big in infectious diseases, cancer

5 years ago

Fueled by Covid prospects, Chinese vaccine developer scores $230M to upscale the whole pipeline

5 years ago

After a slow week, the IPO train is back up and running as 3 more biotechs hop aboard

5 years ago

Is biotech the new bitcoin? A top analyst draws some uncomfortable comparisons to a certain cryptocurrency as 'biotech mania' flourishes

5 years ago

The $1M IPO bonus, decent pay and a nice equity stake to mark the upside: How does Mark McKenna's comp package stack up in the Nasdaq rush?

5 years ago

Old-hat investors Alta Partners snag $275M for their newest next-gen fund, more than double the first iteration from 2018

5 years ago

The SPAC boom continues to churn out heavy capital, as Foresite prices its $175M blank check company and 2 others file

5 years ago

Amid the 'superbug' crisis, a Big Pharma-backed fund scores a meager raise for antibiotics R&D. Is $140M nearly enough?

5 years ago

Royalty Pharma gets more competition as a private equity firm launches $725M royalty-buying fund

5 years ago

Eduardo Bravo returns to bring European biotech in on the SPAC splurge

5 years ago

VC style returns on 'unsexy' public health bets? Gates-backed Adjuvant Capital gathers $300M to mend a 'failure of imagination'

5 years ago

Advent Life Sciences launches two funds totaling $215M, and teams with Harrington Discovery Institute to translate research

5 years ago

A step behind its major exosome challenger, Evox scores $95M round for final leg of race to the clinic

5 years ago

SpyBiotech cashes in on Serum Institute deal, netting $32.5M round for its 'superglue' VLP vaccine tech

5 years ago

Stephen Elledge's Harvard lab takes $17M to birth ImmuneID, a high-throughput antibody startup

5 years ago

GlaxoSmithKline bets another $345M cash on Vir, expanding Covid-19 partnership to flu, RSV and other viruses

5 years ago

Pioneering regenerative med scientist Laura Niklason takes her company public in the latest big SPAC deal. And that gives her a shot at making biotech history

5 years ago

'I’m not trying to rebuild an ego': Neil Woodford appeals to professionals for his comeback biotech fund

5 years ago

Khosla bets big on SPAC boom, raising $1.2 billion for 3 vaguely targeted blank-check companies

5 years ago

A pair of biotechs prepares to hit Nasdaq, as total 2021 IPO raise quickly approaches $3B

5 years ago

Wading deeper into target discovery and validation, Immunai bags $60M to beef up both AI algorithms and lab benches

5 years ago

With crossover round in its pocket, synthetic lethality-focused Cyteir Therapeutics eyes a jump onto Nasdaq

5 years ago

Versant spinout lands $80M to go 'much broader' than the old Roche partnership that birthed it

5 years ago

First page Previous page 82 83 848586 87 88 Next page Last page